Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

This project team will create a users guide or White Paper with recommendations for analysis for analysis and displays for Laboratory Data, with a focus on Phase 2-4 clinical trials and integrated submission documents. There have been 2 previous White Papers on this topic (1 for central tendency in 2013 and 1 for Outliers/Shifts in 2015). This paper will combine two method types and update recommendations given the advancement in interactive options. 



Project LeadsEmail
Charles Beasley
(
, Beasley Pharmaceutical and Biotechnology Consulting
)

Wei Wang (Eli Lilly)

wang_wei_v@lilly.com

Katie Warren (
Christopher Smith, FDAchristopher.smith2@fda.hhs.gov
Nicola Newton, PHUSE Project Assistant
)
katie@phuse

Objectives & Deliverables 

Timelines 

White Paper (initial scope) 

Q3 2022


Status
colourBlue
titleCurrent Status

Q2/3 2022

Final White Paper (initial scope) has been designed and is currently being reviewed by the project team before publishing. 

Q3 2023

Project Closed.



Objectives & Deliverables 

Timelines 

Align on next steps 

Q2 2023
Project MembersOrganisationAmelia PangSanofiDarshan BhattIndustryEdward RauschEli LillyHongli LuMerckKirthi RangarajuPfizerMary NilssonEli LillyMaria DaltonGSKMercy NavarroGenentechMiri Kramer MediwoundNancy BruckenCSGNhi BeasleyFDARaj PhadtareCorvus PharmaceuticalsRobert (Mac) GordonJanssen Research & DevelopmentSumit PradhanIndustryShayami 

Thanabalasundrum

Eli Lilly